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Abstract
Backgound: The epidemiology of travel-associated campylobacteriosis is still largely unclear, and
various known risk factors could only explain limited proportions of the recorded cases.
Methods: Using data from 28,704 notifications of travel-associated campylobacteriosis in Sweden
1997 to 2003 and travel patterns of 16,255 Swedish residents with overnight travel abroad in the
same years, we analysed risks for travel-associated campylobacteriosis in 19 regions of the world,
and looked into the seasonality of the disease in each of these regions.
Results: The highest risk was seen in returning travellers from the Indian subcontinent (1,253/
100,000 travellers), and the lowest in travellers from the other Nordic countries (3/100,000
travellers). In Africa, large differences in risk between regions were noted, with 502 /100,000 in
travellers from East Africa, compared to 76/100,00 from West Africa and 50/100,000 from Central
Africa. A distinct seasonal pattern was seen in all temperate regions with peaks in the summer,
while no or less distinct seasonality was seen in tropical regions. In travellers to the tropics, the
highest risk was seen in children below the age of six.
Conclusions: Data on infections in returning travellers together with good denominator data
could provide comparable data on travel risks in various regions of the world.
Background
Campylobacter infection is a zoonotic disease, observed in
most parts of the world. The disease is caused by Campylo-
bacter jejuni, or less commonly Campylobacter coli. It is esti-
mated to cause 5–14% of diarrhoea, worldwide [1]. The
incubation period is usually 2 to 5 days (range 1 to 10
days), and persons not treated with antibiotics may
excrete the organisms for as long as 7 weeks [2]. Also in
the Western world Campylobacter infection has emerged to
be most important bacterial cause of gastrointestinal
infection. Animals (variety of fowl, swine, cattle, sheep,
dogs, cats, and rodents) are the major reservoir for the
bacteria. Campylobacter does not easily grow in food, but
the critical infective dose is low [3].
Unlike salmonellosis with well-known routes of transmis-
sion, the epidemiology of campylobacteriosis is still
largely unclear, and various known risk factors could only
explain limited proportions of the recorded cases [4].
Known risk factors for the disease include ingestion of
undercooked meat, contaminated food and water or raw
milk, direct contact with pets, farm animals and small
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[3,5-7]. Direct person-to-person transmission between
adults appears to be uncommon. In temperate regions,
campylobacteriosis has a distinct seasonal pattern, with
the peak incidence in the summer months [4,6,8,9], but
seasonal data on campylobacteriosis from tropical regions
are scarce.
Approximately 80 million persons from industrialized
countries travel every year to places in Africa, Asia, Pacific
Islands, Latin America and remote areas of Eastern
Europe, and between, 25 and 50 % of travellers to these
areas experience travellers' diarrhoea [10-12]. About 80 %
of all episodes of traveller's diarrhoea have a bacterial
cause, and Campylobacter infection is a leading cause
together with infections due to enterotoxigenic Escherichia
coli (ETEC), salmonellosis, and shigellosis [11,13].
In this study we have used returning travellers to Sweden
as sentinels to estimate the comparative risks for travel-
associated campylobacteriosis in 19 regions of the world,
and looked into the seasonality of the disease in each of
these regions.
Methods
Notification data on campylobacteriosis
Campylobacteriosis is a notifiable disease according to
the Swedish communicable disease act. Cases are notified
in parallel to the Swedish Institute for Infectious Disease
Control (SMI) by the clinician having seen the patient
(clinical notification) and the laboratory having diag-
nosed the pathogen (laboratory notification). At the SMI
the notifications from the two sources are merged into
case records, using a unique personal identification
number issued to all Swedes, and used in all health care
contacts. The clinical notifications contain epidemiologi-
cal information of relevance, including country of infec-
tion. For this study we retrieved notification information
(age, sex, country of infection and month of infection)
from the national surveillance database [14] on all cases
of campylobacteriosis notified in the period 1997–2003,
with country of infection outside Sweden. All information
in the database is derived from the notifications, and the
data (including "country of infection") are thus based on
the best judgment of the notifying clinician based on the
patient history and knowledge of the characteristics of the
pathogen in question. Since we focused on travel-associ-
ated infections, refugees and newly arrived immigrants
(with incomplete personal identification number) were
sorted out before analysis.
Denominator data on travel patterns
Data on travel patterns were obtained from a commercial
database, the Swedish Travel and Tourist Database (TDB)
[15]. This database contains data from monthly telephone
interviews with 2,000 randomly selected Swedish resi-
dents, with travel-related questions. Out of the total data-
base, containing data from almost 170,000 interviews, we
used 16,255 records of persons with recent overnight
travel outside Sweden. Each record included information
on principal geographical country/region of travel, age,
sex, and month of travel, but no data on any illness. Data
from the TDB are often given as regions rather than coun-
tries, to account for low numbers of respondents outside
the most popular travel destinations.
Statistical methods
The age, sex and geographical distribution of the inter-
viewees in the TDB, were standardised against the total
population of Sweden to give an extrapolation of the
actual number of travellers to each country during the
seven years. We then estimated risks per 100,000 travellers
(divided on the exposures sex, age and region of travel)
using notifications on Campylobacter infection (cases) as
numerator and extrapolated total numbers of travellers




1997 1998 1999 2000 2001 2002 2003 1997–2003
Sweden 1 856 2 616 2 208 2 462 2 839 2 479 2 688 17 148
Travel 
associated
3 013 3 769 4 564 4 932 4 730 3 914 3 782 28 704
Immigrants/
refugees
309 166 167 150 134 111 133 1 170
Unknown 1 703 846 730 870 875 633 544 6 201
Total 6 881 7 397 7 669 8 414 8 578 7 137 7 147 53 223Page 2 of 7
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interviewed persons (controls) were used for the calcula-
tions of 95% confidence intervals (95% CI) for the esti-
mates, using the formula:
eIn risk ± 1.96*√ (1/cases+1/controls)
To adjust for possible confounding and test for interac-
tion, we also calculated odds ratios (OR) with corre-
sponding 95% CI for the same exposures with a logistic
regression model.
In an initial crude analysis, odds ratios (ORs) for all expo-
sures (age, sex, and travel destination) on the outcome
campylobacteriosis were analysed, with the lowest inci-
dence in each category used as reference. Confounding
was then assessed using Mantel-Haenszel stratification.
ORs for exposures with significant association with the
Table 2: Estimated number of Swedish travellers, respondents in the Travel and Tourist database – TDB (controls) and notified 
Swedish cases with travel associated campylobacteriosis 1997–2003, with an unadjusted risk estimate (per 100,000) and multivariate 
odds ratios from a logistic regression model adjusted for the risk factors age, sex month of travel and travel destination.








95% CI Multivariable 
odds ratio
95% CI
Total 67,870,000 16,255 28,704 42.3 41.5–43.1 - -
0 to 6 years 3,300,000 524 1,234 37.4 33.8–41.4 2.34 1.99–2.76
7 to 18 years 8,150,000 1,599 1,957 24.0 22.5–25.7 1.33 1.17–1.51
19 to 45 years 30,520,000 6,708 16,207 53.1 51.6–54.6 2.52 2.27–2.80
46 to 65 years 21,850,000 5,990 8,200 37.5 36.3–38.8 1.50 1.35–1.66
65+ years 4,050,000 1,434 1,106 27.3 25.2–29.5 Reference
Men 36,020,000 8,145 14,694 40.8 39.7–41.9 1.17 1.11–1.23
Women 31,850,000 8,110 14,007 44.0 42.8–45.2 Reference
Nordic countries 22,730,000 5,350 606 2.67 2.45–2.90 Reference
Western Europe 14,800,000 3,584 2,238 15.1 14.3–15.9 5.58 5.05–6.17
Southern Europe 12,070,000 2,931 6,730 55.8 53.4–58.2 22.2 20.1–24.4
Eastern Europe (incl. Baltic Republics) 3,320,000 818 1,414 42.6 39.1–46.4 14.9 13.2–16.8
Eastern Mediterranean 7,740,000 1,817 3,260 42.1 39.8–44.6 14.5 13.0–16.0
Russia and former USSR 260,000 59 96 36.9 26.7–51.1 14.3 10.2–20.1
Arab countries and Iran 220,000 44 433 197 144–268 92.0 66–128
Indian Subcontinent 120,000 31 1,503 1,253 878–1787 532 369–769
East Asia 2,050,000 517 7,910 386 353–422 173 152–197
Australia, New Zealand and the Pacific 450,000 116 75 16.7 12.5–22.3 6.64 48.9–9.02
North Africa 770,000 196 2,788 362 313–418 164 138–195
West Africa 80,000 22 61 76.3 47–124 28.8 17.4–47.6
East Africa 90,000 18 452 502 314–804 243 151–394
Central Africa 30,000 8 15 50.0 21–118 17.4 7.2–41.8
Southern Africa 170,000 42 150 88.2 63–124 37.2 26.0–53.2
North America 2,170,000 503 77 3.5 2.8–4.5 1.39 1.08–1.80
Central America 170,000 43 148 87.1 62–122 35.0 24.6–49.9
Caribbean 380,000 95 299 78.7 62.5–99.1 33.0 25.7–42.4
South America 250,000 61 449 180 138–235 76.0 57–101
aNordic countries = Denmark, Finland, Iceland, Norway; Western Europe = Austria, Belgium, France, Germany, Ireland, Luxembourg, The 
Netherlands, Switzerland, United Kingdom; Southern Europe = Italy, Malta, Monaco, Portugal, Spain; Eastern Europe = Bulgaria, Czech 
Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia; Eastern Mediterranean = Albania, Cyprus, Former Yugoslavia, Greece, 
Israel, Turkey; Russia and former USSR = Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, 
Ukraine, Uzbekistan; Arab countries and Iran = Bahrain, Iraq, Iran, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, United Arab 
Emirates, Yemen; Indian Subcontinent = Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka; East Asia = Brunei, Burma, 
Cambodia, China, Hong Kong, Indonesia, Japan, Laos, Malaysia, Mongolia, North Korea, Philippines, South Korea, Singapore, Taiwan, Thailand, 
Tibet, Viet Nam; Australia, New Zeeland, and the Pacific = American Samoa, Australia, Cook Islands, Fiji, French Polynesia, Guam, Kiribati, 
Marshall Islands, Micronesia, Nauru, New Caledonia, New Zealand, Niue, Palau, Papua New Guinea, Samoa, Tokelau, Tonga, Tuvalu, Vanuatu, 
Wallis and Futuna; North Africa = Algeria, Egypt, Libya, Morocco, Tunisia; West Africa = Benin, Burkina Faso, Cape Verde, Ghana, Guinea, 
Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Senegal, Sierra Leone, The Gambia, Togo; East Africa = Burundi, Djibouti, Eritrea, Ethiopia, 
Kenya, Rwanda, Seychelles, Somalia, Sudan, Tanzania, Uganda; Central Africa = Cameron, Central African Republic, Chad, Congo Brazzaville, 
Equatorial Guinea, Gabon, Niger, Nigeria, Republic of Congo, São Tomé et Principe; Southern Africa = Angola; Botswana, Lesotho, Madagascar, 
Malawi, Mauritius, Mozambique, Namibia, South Africa, Zambia, Zimbabwe; North America = Canada, USA; Central America = Belize, Costa 
Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama; Caribbean = Antigua and Barbuda, Bahamas, Barbados, Bermuda, Cayman 
Islands, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Jamaica, Haiti, Martinique, Netherlands Antilles, Puerto Rico, S:t Christopher 
and Nevis, S:t Lucia / S:t Vincent, Saint Kitts-Nevis, The Grenadines, Trinidad and Tobago, Virgin islands; South America = Bolivia, Brazil, 
Colombia, Ecuador, French Guiana, Guyana, Honduras, Paraguay, Peru, Suriname, Uruguay, Venezuela.Page 3 of 7
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they were shown to contribute significantly to the model
in a Wald test. The presence of significant interaction was
tested with tests for homogeneity. For each region we ana-
lysed seasonality separately (OR for disease per month,
adjusted for age, sex and number of cases/travellers). All
analyses were done using the Stata 6.0 software (Stata
Corporation, College Station, Tx, USA).
Ethical considerations
Notification data is regulated by the Swedish Communi-
cable disease act, and contain full personal identification.
The TDB contains aggregated data only. The Medical Eth-
ics Committee of the Karolinska Institute, Stockholm,
Sweden, approved the study.
Results
Of 53,223 persons notified with campylobacteriosis in
the period 1997 to 2003, 28,704 (54%) were travel-asso-
ciated, corresponding to 42.3 cases per 100,000 travellers
(Table 1). The total number of infections from single
countries both reflected the risk of disease in the various
countries, but to a large extent also the travel pattern of
Swedes. The five most commonly stated countries of
infection were Thailand (n = 6,129), Spain (n = 5,646),
Turkey (n = 1,812), Morocco (n = 1,501), and India (n =
1,086).
The 16,255 respondents with overnight travel outside
Sweden in 1997–2003 from the TDB database corre-
sponded to almost 68 million travel episodes; 78% leisure
trips and 22% business trips (Table 2). Travel to several
countries within one region was quite common, but over-
night stay in more than one region was rare (less than
0.1% of travellers).
Comparing the number of cases with the projected
number of travellers, we estimated the risk for Campylo-
bacter infection in each of the 19 regions under study. The
highest unadjusted risks were seen in the Indian Subcon-
tinent (1,253 per 100 000 travellers; 95 % CI 878–1,787),
East Africa (502 per 100 000; 95 % CI 314–804), East Asia
(386 per 100 000; CI 353–422), North Africa (362 per
100 000; 95 % CI 313–418) and Arab countries/Iran (197
per 100 000; 95 % CI 144–268). Adjusting for age, sex,
and month in the logistic regression model did not
change the rank between the regions (Tables 1 and 2, Fig-
ure 1).
In the crude risk estimate women were at significant
higher risk for campylobacteriosis than men; 44.0 cases
per 100,000 (95 % CI 42.8–45.2) versus 40.8 cases per
100,000 (95 % CI 39.7–41.9). After adjusting for destina-
tion, age, and month in the multivariate logistic regres-
sion model, the risks were reversed with a significantly
higher OR in males (1.17; 95 % CI 1.11–1.23). However,
travel destination was an effect modifier on the associa-
tion between sex and campylobacteriosis, and this higher
risk for males were only significant for travellers returning
from a European country (OR 1.21; 95% CI 1.15–1.27)
(Table 3).
The highest adjusted age risks were seen in young/middle-
aged adults 19–45 years old (OR 2.52; 95 % CI 2.27–
2.80) and in small children 0–6 years old (OR 2.34; 95 %
CI 1.99–2.76). Also the association between age and
campylobacteriosis was modified by travel destination,
and in travellers from tropical destinations, especially
from Africa and Asia/Oceania the highest risk was seen in
the youngest children (Table 3).
Table 3: Multivariable odds ratios (per continent) for the risk of being notified with travel-associated campylobacteriosis from a logistic 
regression model adjusted for the risk factors age, sex month of travel and travel destination. For North America there were too few 
cases for any meaningful results.
All regions Europe Asia + Oceania Africa Latin America + 
Carribean
Age/sex OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Men 1.17 1.11–1.23 1.21 1.15–1.28 1.10 0.93–1.29 1.06 0.83–1.37 0.85 0.62–1.17
Women Reference Reference Reference Reference Reference
0 to 6 
years
2.34 1.99–2.76 2.00 1.67–2.39 9.39 4.66–18.90 7.67 2.76–21.29 2.89 0.89–9.41
7 to 18 
years
1.33 1.17–1.51 1.28 1.11–1.48 1.82 1.16–2.85 1.64 0.91–2.98 1.25 0.47–3.31
19 to 45 
years
2.52 2.27–2.80 2.41 2.27–2.80 4.04 2.81–5.84 3.86 2.44–6.10 2.15 1.01–4.56
46 to 65 
years
1.50 1.35–1.66 1.45 1.29–1.62 1.99 1.38–2.89 1.74 1.11–2.74 1.41 0.65–3.04
65+ years Reference Reference Reference Reference ReferencePage 4 of 7
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with peak risks mainly in the summer; Nordic countries
(peak in June and nadir in March, OR 11.8; 95% CI 5.9–
23.4), Western Europe (peak in June and nadir in Decem-
ber, OR 2.4; 95% CI 1.8–3.3), Eastern Europe (peak in
June and nadir in November, OR 2.4; 95% CI 1.8–3.3),
North America (peak in June and nadir in March, OR 5.8;
95% CI 1.5–23.4), Southern Europe (peak in September
and nadir in January, OR 3.9; 95% CI 3.0–5.0), Northern
Africa (peak in September and nadir in May, OR 4.3; 95%
CI 1.7–11.0), Arab countries and Iran (peak in April and
nadir in August, OR 10.1; 95% CI 1.7–26.4), and Aus-
tralia/New Zealand (peak in November and Nadir in July,
OR 33.1; 95% CI 2.8–394). In the Eastern Mediterranean
the peak risk was seen in the spring (peak in March and
nadir in January, OR 5.1; 95% CI 2.4–10.8), and in Russia
and former USSR in late fall (peak in November and nadir
in May, OR 6.7; 95% CI 1.3–59.2). In the tropical regions
the seasonality was considerably less distinct. In East Asia
the risk peak was in December with nadir in May (OR 4.5;
95% CI 2.8–7.2) and in the Caribbean in February with
nadir in September (OR 7.8; 95% CI 2.2–27.7). In the
Indian Subcontinent, Sub-Saharan Africa, and Central/




In this study we report the risks for travel-associated
campylobacteriosis and seasonality of the risks in various
parts of the world, based on more than 28,000 notified
cases. The large number of cases gives more precise risk
estimates for this disease than in previous studies,
although the estimates are given for quite large regions in
parts of the world with few Swedish travellers. The
denominator data from the TDB has previously been used
in studies on dengue fever [16] and rickettsiosis [17]. We
have also tested the reliability of the TDB by comparing
the TDB data with in-flight passenger data obtained from
some countries with such requirements. For destinations
with many travellers, the two sources of information were
highly compatible, e.g. less than 5 % difference for travel
to Thailand.
Map showing Campylobacter risk per 100 000 returning travellers to Sweden from different regions of the worldFigure 1
Map showing Campylobacter risk per 100 000 returning travellers to Sweden from different regions of the world. In regions 
with a distinct seasonality, the month with the highest risk (OR) is given.Page 5 of 7
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portion of all travel-related Campylobacter infections. One
should therefore be cautious in drawing conclusions from
the magnitude of the figures, and rather focus on the rela-
tive risks between the various regions, as estimated by the
odds ratios. Since the data are all from the same source,
the risk figures from the various regions are directly com-
parable. However, there may be a tendency of investigat-
ing travellers from the tropics more vigorous than
travellers from e.g. the other Nordic countries, thus under-
estimating the risks in nearby countries. However, such
selection bias could likely not explain the huge differences
between say West Africa and East Africa.
Since we have no comparable data on the length of stay
among the cases in our study, we were not able to include
length of stay in our logistic regression model. However,
the TDB clearly shows a longer median stay among travel-
lers in far-away destinations. For instance the median stay
in Spain was 6 nights, while in Thailand it was 14 nights.
On the other hand, only cases detected after the return to
Sweden are included in the analysis. The disease data
therefore mainly reflect infections contracted during the
last week of stay at the travel destination. Differences in
length of travel are therefore to some extent evened out.
It has previously been suggested that the risk of travellers'
diarrhoea is higher during the first two weeks in highly
endemic areas [10,18]. The calculated risks in this study
may therefore be underestimated in travel destinations
with more prolonged stay. However, persons staying long
periods abroad are also less likely to be telephone inter-
viewed in Sweden, balancing the missed cases.
Regional risks
The differences in risk between various regions were con-
siderable, not only between industrialized and develop-
ing countries, but also between different developing
countries. The Indian Subcontinent, East Africa, East Asia,
and North Africa stood out as special high-risk areas. In a
recent Finnish study, the risk of travel associated Campylo-
bacter jejuni infection was 10 per 100,000 travellers return-
ing from Spain and Portugal, and 50, 60, and 80 per
100,000 returning travellers from China, Thailand and
India, respectively [19]. The lower risks, and lesser differ-
ences between the countries may be explained by a much
smaller number of cases (n = 205) to base the risk
estimates on. East Africa and India have also previously
been identified as high-risk areas for travel-associated
diarrhoea of various aetiology [20,21], but the very large
differences in the risk of campylobacteriosis between East
Africa, and West, Central and Southern Africa have to our
knowledge not previously been described.
Age, sex and season (month of travel/infection) were
identified as possible confounders for the association
between travel destination and risk for campylobacterio-
sis and were thus included in the logistic regression
model. All three variables contributed significantly to the
model, but the overall effect of these confounders did not
alter the rank order between the regions in the logistic
regression model compared to the crude analysis.
Age and gender
The highest risks were seen in young adults and small chil-
dren, and especially in the tropics the highest risks were
seen in the youngest. This is consistent with previous find-
ings that in developed countries the disease most of hits
children below the age of 5 years and young adults, while
in developing countries it is most often seen in children
below the age of 2 years, with an annual incidence of 40–
60 % [1]. The data are also consistent with the results from
other studies on traveller's diarrhoeas [11]. De Las Casas
has suggested that the high risk in young adults is due to
a more adventurous lifestyle when it comes to eating hab-
its, and the elevated risk in the youngest is due to
increased faecal/oral contamination and decreased
immunity [22], explanations that seem plausible. An
alternative explanation put forward is that young people
with a greater appetite ingest more bacteria, and thereby
increasing their risk of infection.
In travellers returning from Europe, male gender was an
independent risk factor for Campylobacter infection. This
pattern is also seen in domestically acquired Swedish
campylobacteriosis cases, where 56% of the notified cases
in 2003 were males, and in the US where campylobacteri-
osis is more common in males of all age groups [8,9]. The
higher risk in males in the US has been attributed to sex-
specific differences in food-handling practices and con-
sumption practices as well as a higher susceptibility to gas-
tro-intestinal infections in males [9]. For travel
destinations to tropical or subtropical destinations, the
risk was not influenced by gender, consistent with other
studies on travel-associated diarrhoea [23].
Seasonality
In each of the 19 regions in the study, we looked closely
at the seasonality of the disease. As has previously been
shown [3,6-9], there was a striking seasonal pattern in all
temperate regions, with distinct peaks in the summer. Pre-
viously these summer peaks have been partly attributed to
returning travellers [4], but obviously this could not
explain the same peaks in our study. The magnitude of the
summer peaks was also in the same order in domestic
Swedish cases, as in the returning travellers from other
temperate countries.Page 6 of 7
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In the tropical regions, seasonal peaks of campylobacteri-
osis have not previously been recognized [8]. Also in this
study the seasonal pattern was much less distinct in trop-
ical than in temperate regions, and only in East Asia (peak
incidence in December) and in the Caribbean (peak inci-
dence in February) could a seasonal pattern be discerned.
In a study on US medical students in Mexico, the peak
incidence of Campylobacter infection was seen between
November and April [18]. With only 15 cases and 8 TDB
respondents, our study did not have the power to detect
any seasonality in Central America.
Conclusions
Data on infections in returning travellers together with
good denominator data could provide comparable data
on travel risks in various regions of the world. This study
has revealed large and unexplained regional incidence dif-
ferences, e.g. between East and Central Africa. The very
distinct seasonal pattern seen in all temperate regions
could not be discerned in the tropics.
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